This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Quadrivalent HPV vaccine, Silgard, V501
Description: Gardasil is a vaccine designed to guard against four strains of the human papillomavirus (HPV). The vaccine is designed to prevent the incidence of human papillomavirus (HPV) infection and the associated development of cervical cancer and genital warts. It is approved in the US for the prophylaxis of HPV infection in males and females age 9 to 26 years.
Deal Structure: Merck has entered into a license agreement and collaboration with CSL Limited relating to technology used in Gardasil, as well as other agreements with third parties, including certain academic and research institutions, relating to Gardasil. These agreements include a cross-license and settlement agreement with MedImmune and GlaxoSmithKline for certain patent rights related to HPV vaccines. As a result of these agreements, Merck will pay royalties on the worldwide sales of Gardasil of approximately 24% to 26% in the aggregate. We estimate that 5 percent of all sales will be split among various academic and research institutions and will therefore be unaccounted for in our royalty breakdown.
In December 1997, MedImmune entered into an exclusive license agreement with GSK for certain patents and know-how that have formed the basis for the development of Cervarix. MedImmune then amended its agreement with GSK to allow Merck to sublicense rights to its patents as...See full deal structure in Biomedtracker
Partners: AstraZeneca PLC GlaxoSmithKline plc CSL Limited Sanofi
Additional information available to subscribers only: